BPC-157 vs TB-500.

BPC-157 (sometimes written PL 14736 or "Body Protection Compound 157") is a synthetic pentadecapeptide, a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419 Da). It was designed as a stable partial sequence derived from a larger protein reported in human gastric juice, and is studied chiefly as a cytoprotective and tissue-healing agent. It is not a naturally occurring hormone or an approved drug; nearly all of its reputation rests on animal experiments.

TB-500 is a synthetic peptide sold for research use and widely marketed as "thymosin beta-4 (Tβ4)." Naturally occurring Tβ4 is a 43-amino-acid, ~4.9 kDa actin-sequestering peptide found in nearly all mammalian cells and at high concentration in platelets and wound fluid. Notably, many products labeled "TB-500" are actually a shorter synthetic fragment built around the active actin-binding motif (LKKTET/LKKTETQ) rather than the full-length Tβ4 molecule, so the name is used loosely in the research-chemical market and the exact identity of a given vial is often unverified.

BPC-157's most consistently reported mechanism is modulation of the nitric oxide (NO) system: it promotes endothelial NO production and its protective and vasoactive effects are blunted by NO-synthase blockade (e.g., L-NAME) in animal and tissue models. In endothelial cells it has been reported to activate a Src–caveolin-1–eNOS pathway and to enhance VEGFR2-driven signaling, which is the proposed basis for its pro-angiogenic ("new blood vessel") effects on healing tissue. In cultured tendon fibroblasts it upregulates the growth hormone receptor and supports cell survival and migration. It is also described as interacting with multiple cytoprotective and neurotransmitter (e.g., dopaminergic, serotonergic) systems, though these are largely inferred from preclinical pharmacology rather than direct human data.

The best-characterized function of thymosin beta-4 is binding monomeric G-actin in a 1:1 complex, acting as the principal intracellular actin-sequestering peptide that buffers the pool of unpolymerized actin and thereby modulates cytoskeletal assembly, cell shape, and migration. Through the LKKTET motif and downstream signaling, Tβ4 has been reported in preclinical models to promote keratinocyte and endothelial cell migration, angiogenesis, anti-inflammatory and anti-apoptotic effects, and activation of integrin-linked kinase (ILK)/Akt and laminin-5 pathways relevant to wound repair. These mechanisms are mostly established in cell and animal systems; the degree to which a synthetic LKKTET-type fragment reproduces full-length Tβ4 biology is not firmly established.

The evidence base is overwhelmingly preclinical: hundreds of rodent and in vitro studies (a large fraction from a single Croatian research group led by Predrag Sikiric) report accelerated healing of tendon, muscle, ligament, bone, gut, and nervous tissue, plus gastrointestinal cytoprotection. Human evidence is extremely thin: there is no completed, published, adequately powered randomized controlled trial demonstrating a clinical benefit, and reports of human use (e.g., small uncontrolled case series for joint pain, and an early-phase inflammatory bowel disease program under the code PL 14736) are limited, often unpublished, lack placebo controls, and represent the lowest tiers of clinical evidence. Mechanistic and animal plausibility for tissue repair is genuinely interesting, but it has NOT been confirmed to translate into proven efficacy or safety in people. Any claim that BPC-157 reliably heals injuries in humans goes beyond what the published data support.

Human evidence comes almost entirely from the full-length Tβ4 molecule developed pharmaceutically by RegeneRx and partners, not from research-chemical "TB-500." Topical Tβ4 (RGN-137) was tested in completed Phase 2 dermal-wound trials including a randomized, placebo-controlled study in venous stasis ulcers (ClinicalTrials.gov NCT00832091), and ophthalmic Tβ4 (RGN-259) has advanced to Phase 3 for neurotrophic keratopathy (e.g., the SEER-2 trial, NCT05555589). Preclinical support for dermal, corneal, and cardiac repair is substantial and replicated across labs, as reviewed by Kleinman and Sosne (Vitamins and Hormones, 2016). However, there are no controlled human trials of injectable "TB-500" as sold in the peptide market for musculoskeletal healing, tendon/ligament injury, or athletic recovery; those uses rest on animal data and extrapolation, and the human-vs-preclinical gap is wide.

There is no robust human safety dataset: long-term controlled toxicology and pharmacokinetic data in people are essentially absent, so its safety profile in humans is genuinely unknown. Animal studies have generally reported low acute toxicity, but rodent safety does not establish human safety, and theoretical concerns exist given its angiogenic (blood-vessel-promoting) activity, including unstudied implications for tumor biology. Most material sold online is research-use-only product of unverified identity, purity, and sterility, which adds contamination and mislabeling risks independent of the peptide itself. This entry intentionally gives no dosing, route, or protocol information.

There is no established human safety profile for research-chemical "TB-500"; it is not a licensed drug and is not manufactured to pharmaceutical quality, so identity, purity, sterility, and endotoxin content of marketed vials are unverified. Pharmaceutical full-length Tβ4 has been reasonably well tolerated in controlled topical and ophthalmic trials, but those findings do not transfer to unregulated injectable products. A recurring theoretical concern is that a peptide promoting angiogenesis and cell migration could be undesirable in the setting of occult malignancy, though this is not established as a clinical harm. Contamination, dosing errors, and injection-related risks are the most concrete real-world hazards.

BPC-157 is not approved by the FDA (or other major regulators) for any indication and remains an investigational/research-use-only compound. The FDA placed it in Category 2 of the 503A bulk-substances review in 2023 (citing significant safety questions and restricting compounding); reporting in 2026 indicates it was later removed from that Category 2 list amid a renewed review; removal is not approval and does not establish safety or efficacy.

TB-500/thymosin beta-4 is not approved by the FDA or EMA for any indication; full-length Tβ4 remains investigational (RegeneRx/ReGenTree ophthalmic and dermal programs), and material sold as "TB-500" is research-use-only and not a dietary supplement or medicine. It is prohibited in sport at all times by the World Anti-Doping Agency under class S2 (peptide hormones, growth factors, related substances and mimetics).